-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
This article comes from NEJM Journal Watch New Monoclonal Antibodies Offer Hope for Preventing and Treating Coronavirus Infections.
New monoclonal antibodies bring hope for the prevention and treatment of coronavirus infections.
Comment by Anthony L.
Komaroff, MD two research teams The characteristics of broadly neutralizing antibodies against the coronavirus have been determined
.
Humans face two threats from coronaviruses (such as those that cause severe acute respiratory syndrome [SARS], Middle East respiratory syndrome [MERS], COVID-19, and the common cold)
.
First, the coronavirus that is currently circulating in humans can mutate, which will increase its infectivity and toxicity, and may escape the protective effects of vaccines
.
Second, bats and other mammals carry many new coronaviruses.
These viruses may be transmitted to humans and cause new human diseases
.
In theory, the solution to the above two problems is to develop antibodies that can target the surface structure of all coronaviruses, thereby neutralizing all coronaviruses
.
Two research teams discovered such naturally occurring broadly neutralizing antibodies
.
Antibodies can neutralize all human and animal coronavirus test strains cultivated in the laboratory, and if the above antibodies are given to hamsters immediately before or after inoculation with coronavirus, the antibodies can produce a very strong protective effect
.
Both papers did not test the effect of antibodies on the SARS-CoV-2 delta variant.
The reason may be that the delta variant had not yet appeared at the time of the study
.
Comments If research proves that these broadly neutralizing antibodies are as effective for humans as they are for hamsters, then they may reduce the risk of infection with new variants of SARS-CoV-2, and may also reduce the risk of new coronavirus infecting humans from animals
.
However, their value in disease prevention and treatment remains to be proven by clinical trials
.
In addition, these monoclonal antibodies must be able to achieve sufficiently high yields and be reasonably priced
.
Commented article[1] Tortorici MA et al.
Broad sarbecovirus neutralization by a human monoclonal antibody.
Nature 2021 Sep 2; 597:103.
(https://doi.
org/10.
1038/s41586-021-03817-4)[2 ] Pinto D et al.
Broad betacoronavirus neutralization by a stem helix–specific human antibody.
Science 2021 Sep 3; 373:1109.
(https://doi.
org/10.
1126/science.
abj3321) Journal Watch) is published by NEJM Group.
Internationally renowned doctors are invited to comment on important papers in the medical field to help doctors understand and use the latest developments
.
"NEJM Frontiers of Medicine" is translated several times a week, published on the app and official website, and selected 2-3 articles are published on WeChat
.
Copyright information This article was translated, written or commissioned by the "NEJM Frontiers of Medicine" jointly created by the Jiahui Medical Research and Education Group (J-Med) and the "New England Journal of Medicine" (NEJM)
.
The Chinese translation of the full text and the included diagrams are exclusively authorized by the NEJM Group
.
If you need to reprint, please leave a message or contact nejmqianyan@nejmqianyan.
cn
.
Unauthorized translation is an infringement, and the copyright owner reserves the right to pursue legal liabilities
.
New monoclonal antibodies bring hope for the prevention and treatment of coronavirus infections.
Comment by Anthony L.
Komaroff, MD two research teams The characteristics of broadly neutralizing antibodies against the coronavirus have been determined
.
Humans face two threats from coronaviruses (such as those that cause severe acute respiratory syndrome [SARS], Middle East respiratory syndrome [MERS], COVID-19, and the common cold)
.
First, the coronavirus that is currently circulating in humans can mutate, which will increase its infectivity and toxicity, and may escape the protective effects of vaccines
.
Second, bats and other mammals carry many new coronaviruses.
These viruses may be transmitted to humans and cause new human diseases
.
In theory, the solution to the above two problems is to develop antibodies that can target the surface structure of all coronaviruses, thereby neutralizing all coronaviruses
.
Two research teams discovered such naturally occurring broadly neutralizing antibodies
.
Antibodies can neutralize all human and animal coronavirus test strains cultivated in the laboratory, and if the above antibodies are given to hamsters immediately before or after inoculation with coronavirus, the antibodies can produce a very strong protective effect
.
Both papers did not test the effect of antibodies on the SARS-CoV-2 delta variant.
The reason may be that the delta variant had not yet appeared at the time of the study
.
Comments If research proves that these broadly neutralizing antibodies are as effective for humans as they are for hamsters, then they may reduce the risk of infection with new variants of SARS-CoV-2, and may also reduce the risk of new coronavirus infecting humans from animals
.
However, their value in disease prevention and treatment remains to be proven by clinical trials
.
In addition, these monoclonal antibodies must be able to achieve sufficiently high yields and be reasonably priced
.
Commented article[1] Tortorici MA et al.
Broad sarbecovirus neutralization by a human monoclonal antibody.
Nature 2021 Sep 2; 597:103.
(https://doi.
org/10.
1038/s41586-021-03817-4)[2 ] Pinto D et al.
Broad betacoronavirus neutralization by a stem helix–specific human antibody.
Science 2021 Sep 3; 373:1109.
(https://doi.
org/10.
1126/science.
abj3321) Journal Watch) is published by NEJM Group.
Internationally renowned doctors are invited to comment on important papers in the medical field to help doctors understand and use the latest developments
.
"NEJM Frontiers of Medicine" is translated several times a week, published on the app and official website, and selected 2-3 articles are published on WeChat
.
Copyright information This article was translated, written or commissioned by the "NEJM Frontiers of Medicine" jointly created by the Jiahui Medical Research and Education Group (J-Med) and the "New England Journal of Medicine" (NEJM)
.
The Chinese translation of the full text and the included diagrams are exclusively authorized by the NEJM Group
.
If you need to reprint, please leave a message or contact nejmqianyan@nejmqianyan.
cn
.
Unauthorized translation is an infringement, and the copyright owner reserves the right to pursue legal liabilities
.
